Clinical Trial Update: AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism [Phase 1, Phase 2]

View source ↗

Summary

AZP-3601 completed single-ascending-dose and multiple-ascending-dose studies in healthy subjects and patients with hypoparathyroidism, with results posted Janua…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism

Drugs mentioned

• AZP-3601

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Chronic Hypoparathyroidism | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-01-31